| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() New NICE Prostate Cancer Guideline Focuses on Quality of Life Issues LONDON -- February 27, 2008 -- The National Institute for Health and Clinical Excellence (NICE) has a new guideline on best practice for the diagnosis and treatment of prostate cancer. The guideline, produced for NICE by the National Collaborating Centre for Cancer, will help clinicians to provide coherent and consistent care for men with suspected or diagnosed prostate cancer across England and Wales. Recommendations include: · To help men decide whether to have a prostate biopsy, healthcare professionals should discuss with them their prostate specific antigen (PSA) level, digital rectal examination (DRE) results, and comorbidities, together with their risk factors (including increasing age and black African or black Caribbean ethnicity) and any history of a previous negative prostate biopsy. The serum PSA level alone should not automatically lead to a prostate biopsy. · Men with low-risk localised prostate cancer who are considered suitable for radical treatment should first be offered active surveillance. · Healthcare professionals should ensure that men and their partners have early and ongoing access to specialist erectile dysfunction services. · Healthcare professionals should ensure that men with troublesome urinary symptoms after treatment have access to specialist continence services for assessment, diagnosis, and conservative treatment. · When men with prostate cancer develop biochemical evidence of hormone-refractory disease, their treatment options should be discussed by the urological cancer multidisciplinary team with a view to seeking an oncologist and/or specialist palliative care opinion, as appropriate.
SOURCE: National Institute for Health and Clinical Excellence
|